Screener
BioCryst Pharmaceuticals BCRX Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount?
- BioCryst Pharmaceuticals (BCRX) reported operating lease liability - undiscounted excess amount of $5.67M in Q2 2026.
- How has BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount changed year-over-year?
- BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount decreased by 9.5% year-over-year, from $6.27M to $5.67M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.
Ask your AI about BioCryst Pharmaceuticals's operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude